Regorafenib: all 198 studies that test it
Page 1 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
- Clinical Study of Novel Therapeutic Vaccine for Advanced Solid TumorsRecruitingNCT07567222Phase 1
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Phase 2
- Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma PatientsNot yet recruitingNCT07514455Phase 2
- Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC TrialNot yet recruitingNCT07514429Phase 2
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)Not yet recruitingNCT07495579Phase 2
- STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal CancerRecruitingNCT07213570Phase 2
- Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
- Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]RecruitingNCT07071961Phase 2
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingNCT06992648Phase 3
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal CancerRecruitingNCT06887218Phase 2
- GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.RecruitingNCT06558773Phase 2
- Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingNCT06455254Phase 2
- Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal CancersRecruitingNCT06425133Phase 2
- Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRCNot yet recruitingNCT06322563Phase 2
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283303Phase 1
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283134Phase 1
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingNCT06280105Phase 2
- Regorafenib for Recurrent Meningioma (MIRAGE Trial)RecruitingNCT06275919Phase 2
- A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal CancerRecruitingNCT06200363Phase 1
- KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerRecruitingNCT05985109Phase 2
- Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver MetastasesNot yet recruitingNCT05894837Phase 2
- Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)RecruitingNCT05818267Not applicable
- A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
- Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal CancerRecruitingNCT05462613Phase 2/3
- Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer PatientsNot yet recruitingNCT05426811Phase 1/2
- Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialRecruitingNCT05382741Phase 2
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingNCT05366816Phase 2
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian CancerRecruitingNCT05113368Phase 2
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver MetastasisRecruitingNCT05057052Phase 2
- Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular CarcinomaRecruitingNCT05048017Phase 2
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaRecruitingNCT04625907Phase 1/2
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
- Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone SarcomasRecruitingNCT04055220Not applicable
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingNCT03970447Phase 2/3
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver CancerActive, not recruitingNCT05194293Phase 2Results posted
- RegoNivo vs Standard of Care Chemotherapy in AGOCCompletedNCT04879368Phase 3Results posted
- A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid TumorsCompletedNCT04704154Phase 2Results posted
- Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted
- Study Of Intrabucally Administered Electromagnetic Fields and RegorafenibTerminatedNCT04327700Phase 2Results posted
- Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
- Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerActive, not recruitingNCT04117945Phase 2Results posted
- A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been CompletedCompletedNCT03890731Phase 2Results posted
- Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerCompletedNCT03828799Phase 1/2Results posted
- Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03657641Phase 1/2Results posted
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
- Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung CancerCompletedNCT03520842Phase 2Results posted
- Regorafenib and Nivolumab Simultaneous Combination TherapyCompletedNCT03406871Phase 1Results posted
- An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
- To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal CancerCompletedNCT03215264Phase 1Results posted
- Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRCTerminatedNCT03099486Phase 2Results posted
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
- Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .CompletedNCT02788006Phase 2Results posted
- A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerCompletedNCT02657551Phase 2Results posted
- Phase II Study of Perindopril and Regorafenib in mCRCCompletedNCT02651415Phase 2Results posted
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTerminatedNCT02587650Phase 2Results posted
- Regorafenib in Metastatic Colorectal CancerCompletedNCT02466009Phase 2Results posted
- Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)CompletedNCT02459119Phase 2Results posted
- A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal CancerTerminatedNCT02402036Phase 2Results posted
- Regorafenib Plus Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT02383433Phase 2Results posted
- Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal CancerCompletedNCT02368886Phase 2Results posted
- Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube CancerTerminatedNCT02278783Phase 2Results posted
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
- Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI CancersTerminatedNCT02241720Phase 2Results posted
- Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and SurgeryTerminatedNCT02234180Phase 2Results posted
- Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular DegenerationTerminatedNCT02222207Phase 2Results posted
- Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver MetastasesCompletedNCT02195011Phase 2Results posted
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to RegorafenibCompletedNCT02175095Not applicableResults posted
- Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerTerminatedNCT02168777Phase 1Results posted
- Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GISTCompletedNCT02164240Phase 1Results posted
- Single Agent Regorafenib in Refractory Advanced Biliary CancersCompletedNCT02115542Phase 2Results posted
- Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT02098538Phase 2Results posted
- A Study of Regorafenib in Advanced Pancreatic Cancer PatientsCompletedNCT02080260Phase 2Results posted
- A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line ChemotherapyCompletedNCT02053376Phase 2Results posted
- Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced AngiosarcomaCompletedNCT02048722Phase 2Results posted
- SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma SubtypesCompletedNCT02048371Phase 2Results posted
- Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal AdenocarcinomaCompletedNCT02023333Phase 2Results posted
- Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudyTerminatedNCT01939223Phase 3Results posted
- FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric CancerCompletedNCT01913639Phase 2Results posted
- Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal ImpairmentCompletedNCT01853046Phase 1Results posted
- Study of Regorafenib After Sorafenib in Patients With Hepatocellular CarcinomaCompletedNCT01774344Phase 3Results posted
- Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal CancerCompletedNCT01298570Phase 2Results posted
- First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With RegorafenibCompletedNCT01289821Phase 2Results posted
- Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)CompletedNCT01271712Phase 3Results posted
- Continuous Dosing of BAY73-4506 in Patients With Advanced MalignanciesCompletedNCT01117623Phase 1Results posted
- Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01103323Phase 3Results posted
- Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal TumorCompletedNCT01068769Phase 2Results posted
- A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCCCompletedNCT00664326Phase 2Results posted
- A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal CancerWithdrawnNCT07223567Phase 2
- A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerWithdrawnNCT07137390Phase 1/2
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular CarcinomaWithdrawnNCT06902246Phase 2
- Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the BodyTerminatedNCT06820957Phase 2/3
- Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerWithdrawnNCT06575725Phase 2
- Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
- A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer StudiesActive, not recruitingNCT06246643Phase 2
- Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanActive, not recruitingNCT06199973Phase 3